Glythera Ltd has appointed Robert Lutz as chief scientific officer to help it develop its portfolio of antibody-drug conjugates (ADCs) for difficult-to-treat cancers. Dr Lutz was previously head of translational research and development at ImmunoGen Inc where he was responsible for early-stage ADC development, helping bring eight of the company’s compounds into development.
Also joining Glythera is Jon Roffey who becomes a member of the scientific advisory board. Dr Roffey, a medicinal chemist, comes from Cancer Research Technology.
Glythera announced the appointments on 17 January 2018.
Copyright 2018 Evernow Publishing Ltd